Start practising

PassthePSA › PSA exam guide › Drug Monitoring

PSA section 7 of 8

Drug Monitoring

Know what to measure for a given medicine, when to take the sample, and what the result should change.

items in the paper
8
marks each
2
marks for the section
16 of 200
per item at exam pace
1 min 12 s

Video walkthrough

Drug Monitoring worked through on the exam interface, with the BNF open, in 9 min.

PSA Drug Monitoring: Lithium, Digoxin and Phenytoin (Worked Examples) | Section 7 of 89 minWatch on YouTube

At a glance

Question styleSingle best answer from five
What you doSingle best answer from five
Primary skillKnowing what to measure, when, and what to do with it
BNF useMonitoring requirements in the monograph
On PassthePSASingle best answer in the exam's layout. 234 questions in this section, rated easy to hard.

What this section is really testing

  • Which parameter a drug needs monitored: renal function, liver enzymes, blood counts, electrolytes, a drug level, or a clinical sign.
  • Which kind of monitoring the situation calls for: a baseline before starting, a scheduled check, a test triggered by a symptom, or a timed level.
  • When to sample, especially for drug levels that are only interpretable at a defined time after the dose.
  • What the result changes: continue, adjust, hold, or stop.

A repeatable approach

  1. Identify the drug and its riskWhat organ or system does this drug threaten, or what narrow range must it stay in?
  2. Classify the monitoringBaseline, scheduled, symptom-triggered, or a timed drug level. The question usually fits one.
  3. Find the timingThe monograph's monitoring requirements state when. For levels, the relationship to the dose is the whole point.
  4. Interpret the resultAgainst the stated target or threshold, not against the general reference range alone.
  5. Decide the actionContinue, reduce, hold, stop, or re-sample. The BNF often states the trigger.

Using the BNF for this section

The exam is open book, and the time is short. Know which heading answers which question before you open the monograph.

Drug→Monitoring requirements→Baseline / scheduled / triggered / level→Timing→Result→Action
If you need to knowLook under
What needs checking on this drug?Monitoring requirements
When is the level taken?Monitoring requirements, and the dose section for timing
What is the target range?The monograph, and the treatment summary for the condition
The result is abnormal, now what?Monitoring requirements and side-effects; dose adjustment under renal impairment where relevant

The general technique, with timed lookups, is in the BNF guide.

Four kinds of monitoring

BaselineBefore starting: the value you will compare against.
ScheduledRoutine checks at defined intervals while on the drug.
TriggeredA new symptom or sign demands a test now.
Drug levelA concentration taken at a defined time relative to the dose.

A PSA item usually fits one of the four, and the wrong answers are often the right test from a different category: a scheduled test offered when the symptom needs a triggered one, or a random level when a trough was required.

Common traps

TrapWhy it costs marks
Right test, wrong timeA level drawn at the wrong point after the dose is uninterpretable, however correct the test.
Repeating what is already knownThe test that answered the question last week is not the one that matters now.
Confusing the four kindsA symptom demands a triggered test now, not the next scheduled one.
Reference range as targetFor narrow-margin drugs the therapeutic range, not the lab's normal range, decides the action.
Monitoring the wrong organKnow which system each high-risk drug threatens: kidney, liver, marrow, thyroid, electrolytes.

Areas worth being comfortable with

Not predictions. These are the broad clinical areas this section draws on, taken from the shape of the exam and the BNF; being fluent in them makes the lookup fast.

  • Narrow therapeutic index drugs: lithium, digoxin, gentamicin, vancomycin, theophylline
  • Warfarin and INR
  • Methotrexate, azathioprine and other immunosuppressants
  • Amiodarone: thyroid, liver, lungs
  • ACE inhibitors, diuretics and renal function
  • Statins and liver enzymes
  • Antipsychotics and metabolic monitoring
  • Antiepileptics
  • Biologics and infection screening
  • Steroids: glucose and bone

What this section covers in the bank

Topics with the most drug monitoring questions at the last build, counted by the app's topic search; each link opens that topic in the app.

Worked examples

These are real questions from the PassthePSA bank, free to every visitor. Work each one with the BNF open before you show the answer; at exam pace a 2-mark item has 1 min 12 s.

A 45-year-old on azathioprine for Crohn's disease in remission

Drug Monitoring · TDM-18 · 2 marks · easy

Case

A 45-year-old woman attends the gastroenterology clinic for review of the maintenance treatment for her inflammatory bowel disease, which has been in remission for a year. She reports no sore throat, fever, mouth ulcers or unusual bruising.

PMH: Crohn's disease.

DH: azathioprine 100 mg PO daily.

SH: non-smoker.

On examination: temperature 36.7°C, HR 74/min regular, BP 120/74 mmHg; abdomen soft and non-tender.

Investigations: TPMT activity normal before starting; last Hb 128 g/L (115–165), WCC 5.6 ×10⁹/L (4.0–11.0), platelets 240 ×10⁹/L (150–400). Regular blood monitoring is required while treatment continues.

Question

Select the test most important to monitor regularly because of a serious haematological risk.

(mark it with a tick)

Monitoring options

  1. full blood count and differential
  2. serum calcium and phosphate
  3. thiopurine methyltransferase activity
  4. thyroid function tests and cortisol
  5. vitamin B12 and folate levels
Show the answer and markingHide the answer
Correct answer

full blood count and differential

Marks

2

Explanation

Azathioprine can cause bone marrow suppression, so the full blood count is monitored (and thiopurine methyltransferase activity is checked before starting). Allopurinol markedly increases azathioprine toxicity.

© 2026 PassthePSA · Question TDM-18 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

An 84-year-old on apixaban reviewed after four days of vomiting and diarrhoea

Drug Monitoring · TDM-88 · 2 marks · hard

Case

An 84-year-old woman attends her general practice 2 days after a diarrhoeal illness settled. During a norovirus outbreak at her sheltered housing scheme she had 4 days of vomiting and watery diarrhoea, managed at home; she is now eating again but still feels washed out. She took all her tablets throughout, including on the days she could keep little else down. Her next anticoagulation review, with blood tests, is booked in 6 weeks.

PMH: atrial fibrillation; hypertension; chronic kidney disease.

DH: apixaban 2.5 mg PO twice daily (12-hrly) (atrial fibrillation); ramipril 2.5 mg PO daily (hypertension); amlodipine 5 mg PO daily (hypertension); paracetamol 1 g PO 6-hrly as required. No known drug allergies.

SH: widowed; lives alone in sheltered housing; lifelong non-smoker; no alcohol.

On examination: Temperature 36.6°C, HR 78/min and irregularly irregular, RR 14/min, O2 sat 97% breathing air. BP 126/74 mmHg sitting, 108/66 mmHg after 1 minute standing, with light-headedness on standing. Weight 56 kg, recorded 58 kg at her last review. Dry lips; abdomen soft and non-tender; no bruising and no bleeding.

Investigations: At her last anticoagulation review 6 weeks ago: Na 138 mmol/L (135–145), K 4.6 mmol/L (3.5–5.3), creatinine 110 µmol/L (45–84), eGFR 43 mL/min/1.73 m² (>60); creatinine clearance 31 mL/min by the Cockcroft–Gault equation at her then weight of 58 kg Hb at that review 121 g/L (115–165); no blood tests have been taken since

Question

Select the most appropriate monitoring option for the apixaban prescription at this review.

(mark it with a tick)

Monitoring options

  1. anti-factor Xa activity, before the next apixaban dose
  2. creatinine clearance (Cockcroft–Gault), at the booked review in 6 weeks
  3. creatinine clearance (Cockcroft–Gault), recalculated today
  4. international normalised ratio, today
  5. no blood monitoring at any stage of treatment
Show the answer and markingHide the answer
Correct answer

creatinine clearance (Cockcroft–Gault), recalculated today

Marks

2

Explanation

Two separate pieces of knowledge are being marked. The first is which parameter follows a direct oral anticoagulant: not the INR (BNF, apixaban, Monitoring requirements: 'No routine anticoagulant monitoring required (INR tests are unreliable)', read 22 August 2026), not a routine anti-factor Xa level — the drug has no target range to titrate to — but the kidney function that determines its dose and its licence. Apixaban is avoided below a creatinine clearance of 15 mL/minute and dose-reduced at 15–29 mL/minute, and the clearance is calculated by Cockcroft–Gault, not read off an eGFR.

The second is when. Her stable-state schedule is genuinely the booked one: NICE CKS (Anticoagulation — oral, apixaban scenario, last revised April 2026, read 22 August 2026) repeats the bloods yearly for most people, every 4 months over 75, and by 'CrCl divided by 10' months below 60 mL/minute — about every 3 months at her 31 mL/min. The check booked in 6 weeks respects all of that. What overrides it is the same page's event clause: 'If the person has an intercurrent illness that may impact renal or hepatic function, repeat renal and liver function tests as needed.' Four days of vomiting and diarrhoea, a 2 kg weight loss, a postural blood pressure drop and a continued ACE inhibitor, in a woman whose clearance already sits 2 mL/min above the 15–29 mL/minute band, is exactly the illness that clause describes. If today's clearance has fallen below 15 mL/minute, she is taking a drug she should not be taking at all — and nobody would know until the booked bloods in 6 weeks.

The wrong answers each carry a real fact one step too far: anti-factor Xa assays exist but are reserved for exceptional situations, not reviews; the booked interval is correct arithmetic applied to a schedule the illness has suspended; the INR belongs to her neighbour on warfarin; and 'no monitoring' over-reads the no-INR-clinic message into a claim the dosing criteria on her own chart refute.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question TDM-88 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Before you submit

  • Which of the four kinds of monitoring is this?
  • Is the timing right relative to the dose?
  • Am I judging against the drug's target, not the lab's range?
  • Does the result actually change management?
  • Is the action aimed at the drug, not the number?

Practise this section

Practise Drug Monitoring on its own, or meet it in exam proportions inside a full mock paper. The practice questions are written to reflect the PSA's format and marking closely; PassthePSA is independent of the assessment provider.

Practise Drug Monitoring questions 234 questions, each with a full explanation

Section sizes and marks follow the published PSA blueprint. The BNF headings named here are the current online BNF's. Check any dose or threshold against the BNF before you rely on it; this page teaches the method, the BNF holds the numbers.

Practise Drug Monitoring →